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Abstract Chemotherapy is the basis of treatment of
paracoccidioidomycosis in its various forms. Depend-
ing on the Paracoccidioides brasiliensis virulence,
the status of host immunity, the degree of tissue
involvement and fungal dissemination, treatment can
be extended for long periods with an alarming
frequency of relapses. Association of chemotherapy
with a vaccine to boost the cellular immune response
seemed a relevant project not only to reduce the time
of treatment but also to prevent relapses and improve
the prognosis of anergic cases. The candidate immu-
nogen is the gp43 major diagnostic antigen of
P. brasiliensis and more specifically its derived
peptide P10, carrying the CD4+ T-cell epitope. Both
gp43 and P10 protected Balb/c mice against intra-
tracheal infections with virulent P. brasiliensis strain.
P10 as single peptide or in a multiple-antigen-peptide
(MAP) tetravalent construction was protective with-
out adjuvant either by preimmunization and
intratracheal challenge or as a therapeutic agent in
mice with installed infection. P10 showed additive
protective effects in drug-treated mice stimulating a
Th-1 type immune response with high IFN-c and IL-
12. P10 and few other peptides in the gp43 were
selected by Tepitope algorithm and actually shown to
promiscuously bind several prominent HLA-DR
molecules suggesting that a peptide vaccine could
be devised for a genetically heterogenous population.
P10 was protective in animals turned anergic, was
effective in a DNA minigene vaccine, and increased
the protection by monoclonal antibodies in Balb/c
mice. DNA vaccines and peptide vaccines are
promising therapeutic tools to be explored in the
control of systemic mycoses.
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Introduction
Vaccines have been devised with live attenuated or
inactivated microorganisms that are injected in the
recipient to elicit a protective immune response.
Pathogenic organisms may, however, contain prod-
ucts in the complex mixture of immunogenic
molecules that cause untoward host responses.
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Prophylactic mild infections may not be acceptable in
immune compromised hosts. Isolated protein antigens
mainly in the form of recombinant vaccines have
alternatively been used as reliable and safer immu-
nogens. In the case of tumor cells, the selection of
tumor-specific antigens is important considering the
great majority of self nonmutated proteins which do
not induce an immune response within the limits of
immunological tolerance. Even in autologous tumor
cell preparations, there is the possible inclusion,
however, of components that may aggravate malig-
nancy. Recombinant proteins, that can be adequately
purified for vaccination purposes are still very
complex and carry a mixture of epitopes that induce
B cell and T cell responses. While in many cases a
combined response of Th-2 and T-dependent B cell
lymphocytes with that of Th-1 lymphocytes is most
effective for a balanced immune response, there are
many cases of immunosuppression or immunological
imbalance in which a predominant proinflammatory
Th-1 response should be stimulated for effective host
protection against infectious agents and tumor cells.
Antibodies are beneficial in most cases and constitute
the basis of the current human vaccines, but the cells
involved in their production synthesize a set of
cytokines that may negatively regulate the generally
immunoprotective IFN-c-mediated Th-1 response.
The idea of reducing even further the size of the
immunogen so as to have unique peptide units able to
specifically direct the immune response involving
T-CD4
+, T-CD8
+, and B lymphocytes with the per-
spective of having available timely useful protocols,
is a growing concept, although there are no peptide-
based vaccines so far approved for human use.
Generally peptides are regarded as unstable,
readily degradable molecules with delivery problems
to be solved and, in the case of MHC presentation,
being restricted by the genetic background of the
human recipient. A new comprehension of this area
is, however, emerging with new biotechnological
perspectives. While each peptide has its clearance
in vivo defined by many factors it is also evident that
peptides can be modified for increased stability and
immunogenicity. Furthermore, the degree of circula-
tion of intradermally or subcutaneously injected
peptides can be minimal in the case of dendritic cell
uptake and presentation. For distal targets peptides
can be administered in liposomes, ISCOMs (immu-
nostimulatory complexes), virosomes, microspheres
or in many other associations. Peptides can carry B
and T cell epitopes and target proteins, receptors,
tumor cells, virus and microbial cells. As to immu-
nogenetic restrictions peptides can be selected for
promiscuity in MHC presentation so that they can
still be used in vaccines in a genetically diverse
population. Otherwise, a combination of peptides can
be used to cover both MHC class I and II restrictions
with the aim of fostering immunoprotective
responses. From the cautious remarks by Rothbard
[1] to the updated views of Purcell et al. [2] it is clear
that peptides ‘‘display more drug-like properties than
recombinant proteins or whole pathogen vaccines’’.
The authors listed 31 peptide-based vaccines at
various stages of development against virus and
bacterial infections, cancer, malaria, diabetes, Alz-
heimer’s, and other diseases.
In the present review we focus on vaccination
attempts against paracoccidioidomycosis with the
recent proposition of a peptide vaccine as adjuvant to
chemotherapy.
Attempts at devising vaccines against fungal
diseases
Both the innate immune response and the adaptive
immunity are important for an antifungal protective
effect. Fungi or fungal antigens react with recognition
receptors at the surface of macrophages (Toll-like
receptors, dectin-1, Fc receptors, the mannose recep-
tor, integrins, and other not fully characterized
receptors) and activate them to produce cytokines
(IL-12, IL-10, IL-18) and chemokines (chemokine
receptors CCR2 and CX(3)CR1). Dendritic cells
(DCs) which are nondividing terminally differenti-
ated cells link innate and adaptive immunity and
activate antigen-specific T cells. The differentiation
of monocytes into DCs demonstrated in human cells
has become the essential methodology for the
production of DCs to be used in cancer immunother-
apy protocols. In the mouse, monocytes generate DCs
not only on entry into the lymph and migration to the
lymph nodes but also on extravasation from blood
and homing to the spleen [3]. Both peripheral blood
monocyte subsets with phenotypes Gr1(high)CX(3)-
CR1(int) and GR1(low)CX(3)CR1(high) can give
rise to pulmonary DCs whereas only the latter had the
potential to differentiate into lung macrophages [4].
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Upon maturation, DCs become key antigen-pre-
senting cells (APCs) with increased expression of
MHC molecules. Fungal antigens are processed and
peptide epitopes presented for recognition by T-
lymphocyte receptors. In the case of IL-12-producing
DCs Th-1 cells are induced to proliferate and produce
IFN-c and TNF-a. IL-12 and IL-18 also stimulate
IFN-c production by natural killer (NK) cells. IFN-c-
activated macrophages have increased fungistatic and
fungicidal activities. DCs can also be induced to
produce IL-4 which leads to the proliferation of Th-2
lymphocytes that inhibit the protective cell immunity.
Nevertheless, Th-2 lymphocytes recognize B-cell-
presented antigens and produce cytokines that stim-
ulate B cell maturation and proliferation. Activated B
cells produce antibodies that opsonize fungal ele-
ments for increased phagocytosis. Opsonization is
also achieved with complement and collectins. B
cells can also be activated by T cell-independent
antigens generally represented by carbohydrate struc-
tures. In a comprehensive review on the development
of vaccines against fungal infections, Cutler et al. [5]
listed a number of immunogens from pathogenic
species that could elicit antibodies and cellular
immune responses.
Antibodies were the main mediators of immune
protection particularly against Candida spp., Asper-
gillus spp., Cryptococcus neoformans, and
Pneumocystis carinii. Immunogens comprised carbo-
hydrate structures such as b-1,2-linked mannobiose
and mannotriose [6, 7] and also b-1,3-glucan, a
candidate for a universal fungal vaccine [8, 9].
Further data on Candida b-1,2-oligomannosides and
specific antibodies to them can be found in Travassos
et al. [10]. An interesting aspect was the identifica-
tion of peptides from a phage library able to mimic b-
1,2-linked mannoside epitopes [11]. Peptide
FHENWPS was specifically recognized by anti-b-
1,2-oligomannoside monoclonal antibodies (mAb). It
inhibited binding of mAb to both live yeast cells and
phosphopeptidomannan (PPM). A keyhole limpet
hemocyanin (KHL)-peptide conjugate elicited an
antibody response to yeast PPM which was inhibited
by b-1,2-mannotetraose.
Idiotypic vaccination with mAb KT4 that neutral-
izes the antimicrobial activity of Pichia anomala
killer toxin (KT) elicited antiidiotypic Abs that were
microbicidal and showed in vitro therapeutic effects
[12]. Several linear fragments from the mAb variable
region showed activities similar to the antibody, and a
killer decapeptide (KP) was generated by alanine
substitution of the first amino acid of an active 10-
amino acid fragment. The KP had increased candi-
dacidal activity in vitro and exerted therapeutic effect
in established murine models of vaginal and systemic
candidiasis, cryptococcosis and paracoccidioidomy-
cosis [13–15]. Noticeable is the fact that laminarin
inhibited in a dose dependent manner the cytotoxic
activity of KP suggesting that it may react with b-1,3-
glucan molecules at the surface of the yeast forms.
Secreted aspartyl proteinase and mannoprotein 65 are
two other Candida immunogens that elicit protective
antibodies [16].
The mAb (C7), raised against a C. albicans cell
wall stress mannoprotein, is an IgM that cross-reacted
with cell wall proteins Als3 and enolase, as well as
with the nuclear pore complex Nup88 [17, 18]. MAb
C7 is the first Ab able to exert three different
antifungal activities against C. albicans, namely
inhibition of germination and adhesion and a direct
fungicidal effect which was extensive to C. lusita-
niae, Cryptococcus neoformans, Aspergillus
fumigatus, and Scedosporium prolificans [19].
Recently, mAb C7 proved to be protective in a
murine model of systemic candidiasis [20].
The most well studied antibody protective effect is
that directed to glucuronoxylomannan (GXM) from
Cryptococcus neoformans [9]. Antibodies to GXM
and to oligosaccharides therefrom are protective in
animal models of infection and have a potential to be
used in the clinical treatment of human cryptococco-
sis [21]. A heptasaccharide corresponding to the
immunodominant motif of serotype A GXM has been
produced and it strongly reacted with two different
IgM mAbs to GXM. Conjugation of the heptasac-
charide to human serum albumin rendered a complex
that elicited high-titered IgG responses in mice
administered with complete Freund’s adjuvant. Also
in this case a peptide mimetic of a GXM epitope,
GMDGTQLDRW, was isolated using a protective
human mAb. This peptide linked to either BSA or
tetanus toxoid elicited a protective antibody response
[22].
The major surface glycoprotein (gp120), the p55
and Kexin are Pneumocystis carinii immunogens
with protection mechanisms based on antibodies
and T-cell dependent and independent but CD40L-
dependent, immune responses. In this last case,
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CD4-deficient mice receiving DNA vaccines encod-
ing Kexin and CD40L showed significantly higher
anti-P. carinii IgG titers and opsonic killing of
P. carinii compared with those vaccinated with Kexin
alone [23].
Immune protection involving CD4+T-cells,
CD4+T-, and CD8+T cells and IFN-c has been
described for immunogens from C. neoformans,
Coccidioides spp., and Histoplasma capsulatum
(Hsp60) (reviewed in [5]). Generally, a Th-1 response
based on IL-12 and IFN-c production is effective
against fungal infections. The induction of IL-10 and
other type-2 cytokines is regarded as a limitation to
vaccine success. However, depending on the degree
of inflammation of the Th-1 response, the Th-2
cytokines are essential for a balanced immune
protective response. This balance can be achieved
by incorporation of Th-1 and Th-2-stimulating epi-
topes in the vaccine formulation to achieve protective
immunity while keeping the inflammatory response
within a tolerable limit. In the immune response
against HSP60 from Histoplasma capsulatum or a
polypeptide fraction from this protein (F3), produc-
tion of IL-10 and IFN-c was essential for therapy
efficacy. Apparently in this particular case, the
cytokine milieu determines the conformation of
TCRs making Vb8.1/8.2+ T cells essential for the
protective effect of HSP60 [24].
A competent CD4+-T cell response producing
IFN-c and TNFa is usually the chief protective
mechanism in fungal infections in addition to specific
antibodies as described before. In the course of
CD4+-T cell deficiency as in AIDS patients, however,
CD8+-T cells could have a protective role and this
was examined in Histoplasma-infected mice. In MHC
class II-deficient mice infected with H. capsulatum,
CD8+-T cells were able to limit fungal growth. These
cells expressed both IFN-c and granzyme B and were
cytotoxic to macrophages containing Histoplasma
[25].
Vaccination against Blastomyces dermatitidis
using recombinant BAD1 was not much effective
even when combined with IL-12 used as adjuvant
[26]. Therefore, a genetically engineered BAD1 null
mutant was used as a vaccine. Live yeast of the
null mutant injected subcutaneously protected mice
against a lethal challenge with evidence of steril-
izing immunity [27]. Vaccination in IFN-c or TNF-
a knock-out mice was still effective requiring either
the reciprocal cytokine or GM-CSF. As with H.
capsulatum, antigens from live attenuated yeast can
be cross-presented to DCs hence cross-priming
CD8+ T-cells which can function without either
TNF-a or IFN-c. CD4+T-cell independent CD8+T-
cell memory in these fungi appeared long lasting
(at least 8 weeks post-vaccination). Above all,
immunogens from live attenuated fungi seemed to
recruit multiple arms of the immune response and
be effective even in immunodeficient hosts that can
compensate the lack of certain immune mediators
(TNF-a or IFN-c) by substituting elements (GM-
CSF or TNF-a and GM-CSF, respectively) to
render protective immunity [5].
Immunoprophylaxis of paracoccidioidomycosis
(PCM)
Subcutaneous infection with Paracoccidioides bra-
siliensis was shown to be self-healing inducing strong
DTH reactions. The high T-cell reactivity observed in
susceptible mice could result in immunoprotection or
disease exacerbation depending on the route of a
secondary infection [28]. Immunoprotection was
obtained with a secondary intraperitoneal challenge
associated with persistent cell-mediated immunity of
mixed type-1/type-2. In contrast, exacerbated disease
followed a secondary intravenous challenge which
was associated with anergy and prevalent type-2
immunity. High and low virulence P. brasiliensis
strains were used to induce immunoprotection in
susceptible mice. Immunoprotection was also
achieved against a secondary intratracheal infection
by virulent P. brasiliensis characterized by a combi-
nation of CD4+T cells and CD8+ T cells and the
production of endogenous IFN-c and IL-12 as well as
increased levels of anti-P. brasiliensis specific IgG1
and IgG2a antibodies [29].
Although the protection by primary subcutaneous
infection with high and low virulence P. brasiliensis
seemed quite effective against a secondary infection,
this model refers to prophylactic vaccination as in
other fungal species [5] but not to therapeutic
vaccination against the already installed mycosis that
will be controlled primarily by chemotherapy. It
could, nevertheless, explain the dynamics of multiple
infections in endemic areas with few individuals
developing progressive disease.
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Gp43 the major diagnostic antigen of
P. brasiliensis protects mice against intratracheal
challenge by virulent yeast forms
The 43 kDa glycoprotein (gp43) was isolated from P.
brasiliensis culture supernatant fluids in 1986 [30].
Virtually 100% of patients with paracoccidioidomy-
cosis had antibodies reacting with gp43. Anti-gp43
antibodies from patients submitted to chemotherapy
had lower titers compared with patients with relaps-
ing disease who in turn had antibody titers higher
than patients with installed disease. A decrease of
anti-gp43 IgG, IgA, and IgM was associated with
clinical improvement [31]. Epitopes in gp43 that
elicited a strong antibody response were peptidic in
nature [32] and different isoforms of gp43 including
point mutations and distinct isoelectric points varied
in their reactivity with patients’sera. The gp43 gene
cloning, sequencing, expression, and its polymor-
phism have been reviewed elsewhere [33].
Gp43 being secreted in the fungal environment or
reaching the blood stream is processed and presented
by dendritic cells or B cells inducing a preferential
Th-1 or Th-2- type immune response respectively
[34, 35].
Immunization with gp43 elicits a vigorous IFN-c-
mediated T-CD4+ response that is protective against
the intratracheal challenge by virulent yeasts of this
fungus. The first report showing that gp43 carried an
immunodominant epitope eliciting DTH reactions
was that of Rodrigues and Travassos [36]. The T cell
epitope responsible for DTH reactions, and CD4+
T-cell proliferation, has been mapped to a peptide
called P10 with the sequence: QTLIAIHTLAIRYAN
[37]. The hexapeptide HTLAIR has been shown to be
essential for priming the cellular immune response.
Various 12-amino acid peptides derived from P10
with different flanking sequences were able to induce
lymphoproliferation in sensitized animals. Both P10
as compared to gp43 was equally protective against
the intratracheal challenge of mice with virulent
P. brasiliensis. Gp43 shares 50% identity in the
amino acid sequence with the exo-b-1, 3-D-glucan-
ases from Aspergillus oryzae, Blumeria graminis,
Schizosaccharomyces pombe, Pichia augusta, Sac-
charomyces cerevisae, and Candida albicans. Gp43
has a mutated catalytic site essential for glucanase
activity (NKP instead of NEP) and in consequence is
not an active enzyme. The nucleotide sequence
encoding P10 was conserved which is an important
attribute for a vaccine candidate [33, 38]. No epitope
for CD8+T cells was detected in the gp43 but this is
by no means a closed matter.
Immunization of Balb/c mice with a mammalian
expression vector (VR-gp43) carrying the full gene of
gp43 with CMV promoter induced B and T cell-
mediated immune responses protective against the
intratracheal challenge by virulent P. brasiliensis yeast
forms [39]. The amount of IFN-c produced by gp43-
stimulated lymphoid cells from plasmid immunized
mice was comparable to that using a mitogen, therefore
indicating a powerful immune response. The cellular
immune response in mice immunized with VR-gp43
was maintained for at least 6 months although reduced
to half of the stimulation index obtained 15 days after
immunization. After 3 months of prime intratracheal
infection with 2 · 105 yeast cells of P. brasiliensis
isolate 1914 of high virulence, mice immunized with
VR-gp43 had a significant reduction in CFUs from
lungs, spleen and liver, and the histopathological
image showed lungs with very few and small granu-
lomas with no detectable fungal cells. One of the
advantages of using DNA vaccines is the long-term
expression of constituent genes [40] compared to the
shorter half-life of recombinant proteins. The VR-gp43
vaccination induced anti-gp43 antibodies of subclasses
IgG1 [ IgG2a = IgG2b with little IgE, confirming a
mixed Th-1/Th-2 immune response.
Historically, protective vaccination with plasmid
cDNA encoding a fungal antigen (antigen 2) was
reported for the first time against Coccidioides
immitis [41] followed by the gp43-DNA vaccine in
P. brasiliensis one year later [39].
Attempts at formulating a peptide vaccine
against paracoccidioidomycosis
Peptide P10 derived from P. brasiliensis gp43
contains the T cell epitope that is presented by
MHC class II molecules from three different mouse
haplotypes [37]. The promiscuous nature of P10 was
also extended to the HLA-DR alleles since this
peptide and the analogous peptide at position gp43
(180–194) without the C-terminal asparagine residue
(N-glycosylation site in the original gp43) and with
N-terminal lysine, bound to the 9 prevalent Caucasian
HLA-DR molecules [42].
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By using the TEPITOPE algorithm we also looked
for additional peptides in the gp43 that could also be
promiscuous with respect to HLA-DR binding. This
property is essential for a vaccine candidate consid-
ering the genetic diversity of the target population. In
terms of lymphoproliferation, gp43 (180–194) was
recognized by 53% of patients with treated PCM and
the other promiscuous peptides were recognized by
32–47% of patients; 74% of patients recognized the
combination of 5 promiscuous gp43 peptides [42]. An
expansion of this study with 10 more patients (total of
29) showed that 79% of PCM patients recognized at
least one peptide, and by pooling peptides gp43 (45–
59), gp43 (94–108), gp43 (106–120), gp43 (181–195)
or P10, and gp43 (283–298) the recognition fre-
quency increased to 86% [43]. The TEPITOPE
algorithm scanned 25 Caucasian HLA-DRs and P10
and neighboring peptides were predicted to bind to
90% or more of these molecules.
A reduced number of healthy individuals had
PBMC proliferating with gp43 and even fewer with
gp43 derived peptides. Possibly, these individuals
may have been exposed to P. brasiliensis on a trip to
reserve areas of the fungus or cross-reacted with
related fungal antigens, possibly also exo-b-1,3-D-
glucanases. Looking for sequences homologous to
that of P10 in data banks we found indeed similar
sequences in b-1,3-glucanases from Aspergillus nidu-
lans, Histoplasma capsulatum, Blastomyces
dermatitidis, and Lacazia loboi (a gp43-like protein).
However, similar sequences were also found in
different proteins from a series of bacteria, protozoa,
and even fowl (Gallus gallus). Some of these peptide
sequences were predicted by the TEPITOPE algo-
rithm to bind to HLA-DR molecules (at 3%
threshold) in a way similar to P10. While P10 from
P. brasiliensis was recognized by 21 of 24 HLA-DR
alleles, the peptide from A. nidulans would bind to
18/24 in great contrast with peptides from H. capsul-
atum and B. dermatitidis that showed a very poor
recognition, 5/24 and 3/24 respectively (Table 1). It
seems then that the P10 homologous peptides from
related proteins of H. capsulatum and B. dermatitidis
are not vaccine candidates for a MHC class II-
restricted T-cell activation. Remarkably, completely
unrelated species as Plasmodium yoelli and Strepto-
coccus gordonii had hypothetical proteins with
homologous peptides being recognized by a high
number of HLA-DR molecules (21/24).
Strategic use of peptide vaccine
Stimulation of an effective IFN-c-producing T-helper
response can simultaneously trigger the production of
potentially protective antibodies and the activation of
CD8+ T cells in addition to activation of phagocytic
cells. In the presence of several immunogenic
molecules of the fungal agent, stimulation of one
arm of the immune system may alter a state of early
or installed immunosuppression. It is possible then
that, once complying with the MHC class II restric-
tions, a vaccine could be effective primarily with a
peptide inducing a robust Th-1 immune response. But
fungal infections are regularly treated with drugs,
therefore a peptide vaccine can function as an
adjuvant to reduce the time of treatment, avoid
frequent relapses, improve treatment of anergic cases,
and cope with fungal drug resistance. To expect that a
vaccine made of a polysaccharide, a glycoprotein or
peptide (s) may alone sterilize a massive experimen-
tal infection or an acute or progressive mycosis in
patients without the concomitant use of fungistatic/
fungicidal drugs is not realistic. One should, there-
fore, test the prospective vaccine to be introduced as
an adjuvant to chemotherapy. Successful drug treat-
ment can lyse a great number of fungal cells and the
liberated cell contents may enhance a Th-2/B cell
response with nonprotective antibodies. As the fungal
load is reduced specific antibody titers also wane.
Endogenous or vaccine stimulated specific Th-1
response should help to balance the immune
response, increase the fungal clearance and shorten
the recovery period.
Experiments with Balb/c mice that respond quite
well to P10 immunization in terms of IFN-c produc-
tion and anti-fungal protection effects, served to
confirm some of these expected responses.
P10 immunization was coupled to chemotherapy
in intratracheally infected Balb/c mice using two
protocols. Infected mice with yeast cells of highly
virulent P. brasiliensis underwent P10 and/or drug
treatment starting after 48 h of infection. In the
second protocol, P10 and/or drug treatment started
after 30 days infection. The treatment continued for
30 days, during which groups of mice received
intraperitoneal doses of itraconazole, fluconazole,
ketoconazole, sulfamethoxazole or trimethoprim-sul-
famethoxazole every 24 h. Amphotericin B was
administered every 48 h. Immunization with P10
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was carried out weekly for 4 weeks, once in complete
Freund’s adjuvant and three times in incomplete
Freund’s adjuvant [44].
A significant reduction in the fungal load (mea-
sured as CFUs) was observed in both groups, either
immunized with P10 only or treated with antifungal
drugs, with an additive protective effect obtained
with the combination of both. Unexpectedly, animals
treated with sulfamethoxazole, showed early protec-
tion followed by relapse, but the association of
sulfamethoxazole and P10 vaccination successfully
controlled the infection. With the second protocol
that aimed to reproduce the patient’s condition of
established infection, the fungal burden was exam-
ined after 60 and 120 days of infection. Also in this
case, an additive protective effect of P10 immuniza-
tion and drug treatment was observed, with 60 to 80%
reduction in lung CFUs. As examined in lung
homogenates chemotherapy led to a predominant
Th2 response with increased production of IL-4 and
IL-10 as hypothesized above. P10 vaccination stim-
ulated a Th1 response, rich in IFN-c and IL-12
Table 1 In silico prediction of HLA-DR binding of various peptides, homologous to P. brasiliensis P10, from proteins of different
species
Species Protein description Position from
N-ta methionine
Sequence(mostly from
BLAST/NCBI data base)
Number
of HLA-DR
molecules
recognized
(at 3% threshold)
P. brasiliensis gp43 181–195 Q T L I A I H T L A I R Y A N 21
Aspergillus
nidulans
glucanase-like
protein
251–266 E Q T I L A F E T L A Q R Y L 18
Histoplasma
capsulatumb
b-glucanase 180–194 A Q T L N A L R A L A E R Y A 5
Blastomyces
dermatitidisb
b-1,3-glucanase 185–199 A Q T L N A V R A L A E R Y A 3
Bacillus
thurigiensis
Bacillus cereus
transcriptional
regulator Ara C family
236–252 N N G I I A I - T L A I R Y A I D G 4
Lacazia loboi gp43-like protein AAW21849c
21–37
K Q T L A A I R A L A N R Y A K R 13
Gallus gallus ortholog of
rat PB-cadherin
545–563 K G T L L A V H T L A V S Y T A G V D 13
Herpetosiphon
auranticus
UDP-N-acetylmuramoyl
alanyl-D-glutamyl-
2,6-dipimelate—
D-alanyl-D-alanyl ligase
114–131 V D Q T L T A M H R L A T R Y R Q Q 12
Desulfotalea
psychrophila
Similar to dolichyl
phosphate mannose
synthase
284–300 A L P L I A C H T L A I I Y F C C 18
Plasmodium
yoelli yoelli
Hypothetical protein XP727303c
786–803
I E L L I S I L T L S I R Y I L R N 21
Streptococcus
gordoni
Hypothetical protein 477–491 G L S M I H T L A I I Y A V V 21
Gibberella zeae Hypothetical protein 27–42 L N S Q T I A I H T L A H Q D S 3
Rhodococcus
erythropolis
Hypothetical protein 65–81 F G G L I A S G I H T L A I L Q R 10
a N-t, N-terminal
b Data base for H. capsulatum, Hc, and B. dermatitidis, Bd (http://www.genome.wustl.edu/)
c Assession number in the BLAST/NCBI data base, for incomplete sequence indicating the corresponding peptide fragment
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without suppressing the Th-2 elements of the immune
response [44]. It should be pointed out that these
experiments could be further optimized with pro-
longed treatment aiming complete infection control.
In acute or subacute forms of PCM patients may
have high antibody titers accompanied by severe
depression of cell-immunity [45]. In an attempt to
experimentally reproduce these conditions, Balb/c
mice were treated with dexamethasone-21 phosphate
added to drinking water. After 30 days animals
showed negative DTH. Infected animals, treated with
0.15 mg/kg of dexamethazone and injected with
P. brasiliensis crude antigen also showed negative
DTH after the same period. Mice were then infected
with a virulent P. brasiliensis isolate and after fifteen
days were submitted to chemotherapy and/or P10
immunization. The association of drugs and P10
immunization conferred additive protection. A sig-
nificant increase in IL-12 and IFN-c and decrease of
IL-4 and IL-10 was observed in mice immunized with
P10 alone or in association with antifungal drugs
[Marques et al., unpublished results]. These results
suggest that P10 immunization can be effective in the
case of anergic patients.
Peptide delivery and adjuvants
Peptide delivery using formulations that did not
include CFA has also been a concern of our group.
Immunization with the P10 minigene in plasmid
DNA associated or not with a plasmid carrying a
murine IL-12 insert, was tested in Balb/c mice
intratracheally infected with a virulent isolate
(Pb18) of P. brasiliensis. Such immunization elicited
significant reduction of fungal burden in lung, spleen,
and liver. A significant production of IL-12 and IFN-c
and reduction of IL-4 levels in lung homogenates
were observed with the DNA vaccination [Rittner
et al., unpublished results].
Another attempt involved a MAP (multiple anti-
gen peptide) construction. MAP-10 or M10 had four
equal LIAIHTLAIRYAN (N-terminal QT-less P10)
chains synthesized on a branched lysine core
containing glycine at the C-terminal position. Prolif-
eration of lymph node cells from P10 or M10-
sensitized mice was identical when stimulated in
vitro with either P10 or M10. Mice immunized with a
single dose of M10 without adjuvant and challenged
i.t. with P. brasiliensis showed fewer lung, spleen and
liver CFUs and few or no yeasts in lung histopath-
ological sections [46].
In Balb/c mice with established 30-day intratrac-
heal infection, the therapeutic effect of P10 was
tested alone or mixed with adjuvants: alum, mono-
phosphoryl lipid A or complete Freund’s adjuvant
(Fig. 1). Surprisingly, P10 administered in PBS was
the most effective preparation with a very significant
reduction in the CFUs from the lungs with no fungi
detected in spleens and livers. Modifications of N and
C termini of a peptide are known to prevent its
degradation by exopeptidases [47]. Such modifica-
tions usually involve N-acetylation and C-amidation.
In the experiments described, P10 was always used in
the C-amidated form.
Association of P10 and protective anti-gp43
monoclonal antibodies
An association of P10 with protective anti-gp43
mAbs has also being explored. Recently, it has been
reported that anti-gp70 mAbs were protective against
experimental PCM [48]. Both gp43 and gp70 are
markers for monitoring the regression of PCM
through their decreased antigenemia and specific
antibody response in patients submitted to chemo-
therapy [49, 50].
The protective effect of anti-gp43 mAbs injected
i.p. on the intratracheal infection with P. brasiliensis
was examined in Balb/c mice (unpublished results).
The reactivity of mAb 3E, the most efficient mAb in
the reduction of fungal burden and phagocytosis
in vitro, against a panel of gp43 derived peptides
suggested that the recognized epitope could lie within
the sequence NHVRIPIGYWAV shared with Asper-
gillus fumigatus, A. oryzae and B. graminis internal
sequences of b-1,3-glucanases. This peptide would
represent with P10, another candidate for a peptide
vaccine against PCM.
In a P10-preimmunization protocol, which is not
the most effective in the absence of a simultaneous
infection and chemotherapy, mAbs were tested as
protective agents. The association of P10-preimmu-
nization and mAb 3E administered 24 h before
intratracheal challenge with virulent P. brasiliensis
yeasts resulted in the best protection using short-term
protocols in comparison with a nonprotective mAb.
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Significantly, this association yielded the highest
IFN-c and IL-12 levels and fewest lung CFUs
(Table 2).
Short-term protocols (30 to 45 days) have the
advantage of allowing repeated experiments to define
a certain response. However, longer periods of
treatment and observation may lead to even more
effective results, aiming at sterilization in experi-
mental models with massive infection loads.
Concluding remarks
Chemotherapy is the basic treatment of systemic
mycoses. In cases of immunodepression and even of
anergy the fungal elements, usually yeast forms,
proliferate intensely because of deficient innate and
adaptive immune response. In these conditions,
chemotherapy is less efficient and requires long
periods of treatment with the risk of relapsing
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Fig. 1 Therapeutic effect of P10 administered alone or with
adjuvants. Balb/c mice (five per group) were infected with
3 · 105 cells of Paracoccidioides brasiliensis Pb18 and after
30 days vaccination with P10 alone or mixed with adjuvants
was initiated. P10 was diluted in 20% DMSO and PBS and
administered at 20 lg per animal. Alum and complete Freund’s
adjuvant (CFA) were used in the same volume (50 ll) as for
P10 solution. Monophosphoryl lipid A (MPLA) was used at
1 lg per animal. Thirty days after therapy mice were sacrificed
totaling 90 days of infection. Colony forming units (CFUs)
were determined in the lung (L), spleen (S) and liver (V) of
mice. Values are means with standard deviations
Table 2 Association of monoclonal antibody against gp43 and immunization with P10 in Balb/c mice infected i.t. for 45 days (short
period) with P. brasiliensis isolate Pb18
Balb/c micea Lung CFUse Cytokine (ng/g/ml)
Treatmentb CFU/g tissue IL-4 IL-10 IL-12 IFN-c
Sham infection - 0.81 ± 0.38 1.30 ± 0.60 5.56 ± 2.41 0.33 ± 0.39
Only infectedc 26,185 ± 2,914 1.44 ± 0.16 2.87 ± 1.27 11.02 ± 0.564 0.78 ± 0.57
Immunized P10 13,291 ± 1,551 1.26 ± 0.16 7.54 ± 1.01 15.30 ± 2.39 7.42 ± 1.53
mAb 32H (nonprotective)d 31,523 ± 7,991 1.20 ± 0.25 13.40 ± 2.17 4.28 ± 6.52 3.20 ± 1.35
mAb 3E (protective)d 19,220 ± 2,279 1.23 ± 0.17 11.12 ± 0.14 13.50 ± 1.52 6.35 ± 0.68
P10 and mAb 32H 20,924 ± 4,359 1.39 ± 0.01 9.15 ± 1.53 10.78 ± 2.51 5.06 ± 0.86
P10 and mAb 3E 8,800 ± 1,886 0.75 ± 0.17 6.89 ± 1.88 22.24 ± 1.77 8.87 ± 1.44
a Male, 6–8 week-old Balb/c mice, groups of 10
b Animals were preimmunized with P10 (4 doses of 20 lg, the first in CFA and the others in IFA ) before infection
c Intratracheal infection with 3 · 105 Pb18 yeast forms
d Antibodies purified in protein A and LPS-removing detoxigel injected i.p. 24 h before i.t. challenge
e CFUs, colony forming units
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disease. Therapeutic vaccination with fungal antigens
may boost the cell immune response and add to the
protective effect of chemotherapy even counteracting
the possibility of relapsing disease.
Of all prospective vaccines, DNA-based vaccines
and peptides appear as the most promising because
they can be obtained in large quantities at high
degrees of purity for human immunization. The
results with P10 show that a single peptide had a
remarkable therapeutic effect even without adjuvant.
It also showed that protection can be achieved in
mice with established disease, undergoing chemo-
therapy, by stimulating one arm of the immune
response, that of IFN-c-mediated CD4+ T-cells. The
present results also show that monoclonal antibodies
can be protective against paracoccidioidomycosis and
that a new peptide, carrying a B cell epitope can also
be tested in a vaccine to foster a balanced immune
response.
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